Evidence map›Paper›PMID 33293793›Full record

ArticleDrug design, development and therapy2020

Cytotoxic and Antiproliferative Effects of β-Mangostin on Rat C6 Glioma Cells Depend on Oxidative Stress Induction via PI3K/AKT/mTOR Pathway Inhibition.

Kaiqiang Li, Lingling Wu, Yili Chen, Yuanyuan Li, Qianni Wang, Min Li, Ke Hao, Wei Zhang, Shanshan Jiang, Zhen Wang

Open access · goldAbstract read
In one paragraph

Article in Drug design, development and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Research progress on platelets in glioma.Chinese medical journal · 2025
    Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Mangostanin, a Xanthone Derived fromPharmaceuticals (Basel, Switzerland) · 2022
    Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Kaiqiang Li *School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou 325027, People's Republic of China.ORCID 0000-0003-4307-0845
Lingling Wu *School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou 325027, People's Republic of China.
Yili Chen *College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014, People's Republic of China.
Yuanyuan LiSchool of Pharmacy, Hangzhou Medical College, Hangzhou 310014, People's Republic of China.ORCID 0000-0002-5418-4701
Qianni WangSchool of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou 325027, People's Republic of China.
Min LiRehabilitation & Sports Medicine Research Institute of Zhejiang Province, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou 310014, People's Republic of China.
Ke HaoResearch Center of Blood Transfusion Medicine, Ministry of Education Key Laboratory of Laboratory Medicine, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou 310014, People's Republic of China.
Wei ZhangRehabilitation & Sports Medicine Research Institute of Zhejiang Province, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou 310014, People's Republic of China.
Shanshan JiangResearch Center of Blood Transfusion Medicine, Ministry of Education Key Laboratory of Laboratory Medicine, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou 310014, People's Republic of China.
Zhen WangSchool of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou 325027, People's Republic of China.ORCID 0000-0002-8581-4649
Wenzhou Medical University · CNZhejiang Provincial People's Hospital · CNHangzhou Medical College · CNZhejiang University of Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGlioma is the most common malignant tumor of the nervous system, which accounts for more than 45% of central nervous system tumors and seriously threatens our health. Because of high mortality rate, limitations, and many complications of traditional treatment methods, new treatment methods are urgently needed. β-Mangostin is a natural compound derived from the fruit of MATERIALS AND

methodsTo study the effect of β-mangostin on glioma cells, cell viability assay, reactive oxygen species production, cell cycle, apoptosis, and mitochondrial membrane potential were evaluated in the C6 cell line in vitro. Immunofluorescence and Western blotting were used to analyze protein expression and phosphorylation to study its mechanism of action. A subcutaneous xenograft model was used to investigate the effect of β-mangostin on tumorigenesis in vivo.

resultsWe found that β-mangostin can inhibit glioma cell growth and induce oxidative damage in vitro. In addition, it reduces the phosphorylated form levels of PI3K, AKT and mTOR. Furthermore, the phosphorylated form levels of PI3K, AKT and mTOR were increased after the PI3K inhibitor was added. In vivo experiments showed that β-mangostin can inhibit tumor growth as shown by its reduced size and weight.

conclusionThis study suggests that β-mangostin can inhibit cell proliferation and induce oxidative damage in cells. It is the first study to demonstrate that β-mangostin induces oxidative damage in glioma cells by inhibiting the PI3K/AKT/mTOR signaling pathway.

Indexed as

AnimalsAntineoplastic Agents, PhytogenicApoptosisCell ProliferationCell SurvivalDrug Screening Assays, AntitumorGarcinia mangostanaGliomaOxidative StressPhosphatidylinositol 3-KinasesPlant ExtractsProto-Oncogene Proteins c-aktRatsTOR Serine-Threonine KinasesTumor Cells, CulturedXanthonesAntineoplastic Agents, PhytogenicmangostinmTOR protein, ratPhosphatidylinositol 3-KinasesPlant ExtractsProto-Oncogene Proteins c-aktTOR Serine-Threonine KinasesXanthonesGarcinia mangostana L.gliomaoxidative damagePI3K/AKT/mTOR

Identifiers

PMID33293793
PMCPMC7718963
OpenAlexW3107141127

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.